Evelo Biosciences, Inc. (EVLO) DCF Valuation
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Evelo Biosciences, Inc. (EVLO) Bundle
Explore the financial prospects of Evelo Biosciences, Inc. (EVLO) with our user-friendly DCF Calculator! Enter your assumptions for growth, margins, and expenses to determine the intrinsic value of Evelo Biosciences, Inc. (EVLO) and inform your investment decisions.
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2018 |
AY2 2019 |
AY3 2020 |
AY4 2021 |
AY5 2022 |
FY1 2023 |
FY2 2024 |
FY3 2025 |
FY4 2026 |
FY5 2027 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EBITDA | -58.1 | -86.4 | -91.9 | -115.4 | -106.3 | .0 | .0 | .0 | .0 | .0 |
EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Depreciation | .0 | .0 | 2.0 | 2.2 | 2.1 | .0 | .0 | .0 | .0 | .0 |
Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
EBIT | -58.1 | -86.4 | -93.9 | -117.6 | -108.4 | .0 | .0 | .0 | .0 | .0 |
EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Total Cash | 147.9 | 77.8 | 68.9 | 68.4 | 47.9 | .0 | .0 | .0 | .0 | .0 |
Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Accounts Payable | 1.5 | .6 | 1.4 | 1.6 | 1.8 | .0 | .0 | .0 | .0 | .0 |
Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Capital Expenditure | -5.5 | -3.0 | -1.3 | -1.5 | -.6 | .0 | .0 | .0 | .0 | .0 |
Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
Tax Rate, % | -0.81868 | -0.81868 | -0.81868 | -0.81868 | -0.81868 | -0.81868 | -0.81868 | -0.81868 | -0.81868 | -0.81868 |
EBITAT | -55.0 | -86.6 | -94.3 | -118.0 | -109.3 | .0 | .0 | .0 | .0 | .0 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -58.9 | -90.5 | -92.8 | -117.2 | -107.7 | -1.8 | .0 | .0 | .0 | .0 |
WACC, % | 8.64 | 9.14 | 9.14 | 9.14 | 9.14 | 9.04 | 9.04 | 9.04 | 9.04 | 9.04 |
PV UFCF | ||||||||||
SUM PV UFCF | -1.6 | |||||||||
Long Term Growth Rate, % | 2.00 | |||||||||
Free cash flow (T + 1) | 0 | |||||||||
Terminal Value | 0 | |||||||||
Present Terminal Value | 0 | |||||||||
Enterprise Value | -2 | |||||||||
Net Debt | 3 | |||||||||
Equity Value | -5 | |||||||||
Diluted Shares Outstanding, MM | 4 | |||||||||
Equity Value Per Share | -1.10 |
What You Will Get
- Pre-Filled Financial Model: Evelo Biosciences' actual data facilitates accurate DCF valuation.
- Full Forecast Control: Modify revenue growth, profit margins, WACC, and other essential metrics.
- Instant Calculations: Real-time updates guarantee you see outcomes as you adjust inputs.
- Investor-Ready Template: A polished Excel file crafted for high-quality valuation presentations.
- Customizable and Reusable: Designed for adaptability, enabling repeated use for in-depth forecasts.
Key Features
- Comprehensive Financial Data: Gain access to precise historical data and future forecasts tailored for Evelo Biosciences, Inc. (EVLO).
- Adjustable Forecast Parameters: Modify highlighted fields such as WACC, growth rates, and profit margins to fit your analysis.
- Real-Time Calculations: Enjoy automatic updates for DCF, Net Present Value (NPV), and cash flow assessments.
- User-Friendly Dashboard: Utilize clear charts and summaries to easily interpret your valuation findings.
- Designed for All Skill Levels: An intuitive layout suitable for investors, CFOs, and consultants alike.
How It Works
- Download the Template: Gain immediate access to the Excel-based EVLO DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and other variables.
- Instant Calculations: The model automatically recalculates Evelo's intrinsic value.
- Test Scenarios: Experiment with different assumptions to assess potential valuation shifts.
- Analyze and Decide: Leverage the results to inform your investment or financial analysis.
Why Choose This Calculator for Evelo Biosciences, Inc. (EVLO)?
- Precision: Utilizes accurate financial data specific to Evelo Biosciences.
- Adaptability: Allows users to easily adjust and experiment with various inputs.
- Efficiency: Bypass the complexities of creating a DCF model from the ground up.
- Expert-Level: Crafted with the insight and precision expected at the CFO level.
- Intuitive: Simple interface suitable for users without extensive financial modeling skills.
Who Should Use This Product?
- Investors: Evaluate Evelo Biosciences’ valuation prior to making investment decisions.
- CFOs and Financial Analysts: Optimize valuation methodologies and validate financial forecasts.
- Startup Founders: Understand the valuation strategies of biotech companies like Evelo.
- Consultants: Provide detailed valuation analyses and reports for clients in the biotech sector.
- Students and Educators: Utilize real-time data to learn and teach valuation practices in biotechnology.
What the Template Contains
- Pre-Filled Data: Incorporates Evelo Biosciences' historical financials and projections.
- Discounted Cash Flow Model: Customizable DCF valuation model with automated calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for computing WACC based on user-defined inputs.
- Key Financial Ratios: Evaluate Evelo's profitability, efficiency, and financial leverage.
- Customizable Inputs: Easily modify revenue growth, margins, and tax rates.
- Clear Dashboard: Visualizations and tables summarizing essential valuation outcomes.